|
|
|
| Effect of Ulinastatin on Serum Inflammatory Indexes and Intestinal Barrier Function in SAP Patients |
| CHEN Ying, LIU Zheng'ai, FANG Liang, et al |
| The Central Hospital of Huanggang, Hubei Huanggang 438000, China |
|
|
|
|
Abstract Objectives: To investigate the effect of ulinastatin on serum inflammatory factors and intestinal mucosal barrier function in patients with severe acute pancreatitis (SAP). Methods:From January 2015 to January 2019, 80 patients with SAP in Gastroenterology Department of our hospital were selected as the main subjects of study and divided into treatment group (n=41, treated with ulinastatin on the basis of routine treatment) and control group (n=39, treated with routine treatment) according to the random digital table method. Analysis was applied to the changes of serum inflammatory factors [tumor necrosis factor-α (TNF- α) and IL-6, 10, 17 (IL-6,IL-10,IL-17)] in the two groups before and after treatment, and the changes of intestinal barrier function index [endotoxin (ET), serum intestinal fatty acid binding protein (IFABP), diamine oxidase (DAO), D-lactic acid (D-Lac)]. The therapeutic effect and mortality after 7 days of SAP were observed. Results: The total effective rate in the treatment group was 92.68%, which was significantly higher than that in the control group (76.92%, P<0.05). Comparatively, the levels of TNF-1, IL-6, IL-10, IL-17, ET, IFABP, DAO and D-Lac in both groups decreased significantly, while IL-10 increased significantly (Pall< 0.01), after treatment. Compared with the control group, the levels of serum inflammatory factors and intestinal barrier function in the treatment group were significantly improved(Pall< 0.01).The 7-day-mortality rate of the treatment group was 4.88%, which was significantly lower than that of the control group (20.51%,P<0.05). Conclusion: Ulinastatin could significantly inhibit the level of serum inflammatory factors in patients with SAP, improve the protective effect of intestinal mucosal barrier and reduce the short-term mortality of SAP patients. The curative effect is ideal.So it has clinical application value.
|
|
|
|
|
|
[1] 谭瓛,龙玉梅.乌司他丁治疗重症急性胰腺炎的临床疗效及对血清TNF-αIL-10水平的影响[J].河北医学,2016,22(11):1763~1765.
[2] 黄梅,郑惠之,赵荣.大承气汤合大柴胡汤加芒硝外敷联合乌司他丁对重症急性胰腺炎患者腹内压及血清炎性因子的影响[J].中国中医急症,2018,27(11):136~139.
[3] 王兴鹏,李兆申,袁耀宗,等.中国急性胰腺炎诊治指南(2013,上海)[J].中华胰腺病杂志,2013,13(2):73~78.
[4] 曾志雄,姚玉珍,余卫峰,等.介入超声在治疗重症急性胰腺炎中的应用[J].医学影像学杂志,2016,26(5):856~859.
[5] 李百强,杨娜,叶博,等.重症急性胰腺炎并发持续性炎症反应-免疫抑制-分解代谢综合征临床分析[J].医学研究生学报,2017,30(7):719~724.
[6] 崔翔.血清sVCAM-1、TNF-α、HDL-C水平变化与冠心病患者NF-κB的相关性研究[J].标记免疫分析与临床,2018,25(11):41~44.
[7] 古凌燕,宋振顺.参麦注射液对重症急性胰腺炎大鼠肠黏膜屏障功能的保护作用[J].川北医学院学报,2018,33(4):557~560.
[8] 杨晓钟,马雯霞,王军艳.乌司他丁不同给药模式联合奥曲肽对老年重症急性胰腺炎患者腹内高压及肠黏膜功能及对p38MAPK信号通路介导的炎症反应的影响[J].临床急诊杂志,2018,19(8):16~20.
[9] 刘海,彭晓静,郭平选,等.创伤失血性休克大鼠血清D-乳酸、二胺氧化酶和内毒素的变化及其对肠黏膜损伤的意义[J].西部医学,2019,31(3):48~51.
[10] 徐小彭,李敏雄,黄永鹏,等.乌司他丁治疗老年急性重症胰腺炎的临床研究[J].中国临床药理学杂志,2017,33(21):20~23.
[11] 李群,朱平.乌司他丁治疗重型急性胰腺炎的疗效及其对患者血清炎症因子水平的影响[J].山东医药,2015,55(32):64~65. |
|
|
|
2020, Vol. 26 
